New BEAM Patient Testimonial from Mother in Chili

Dear Doctor,

You will not believe me, but yesterday we remembered you and I told my sister that I was going to write to tell you the positive evolution of my son Paulo.

With great joy I tell you that Paulo has evolved in an extraordinary way, especially in the last 3 months. Practically this normal, passed the fears, the insecurities, the constant depression that maintained, is totally autonomous, works, shares, talks, goes out with his friends and acts like a normal person. I dare say he has achieved a 95% recovery. His doctor has eliminated the Azymol, has lowered the Quetiapina and soon will begin to lower the Depurol. I hope in God that he continues to evolve further to continue to reduce the medications, but with all that he has recovered, I can have the peace of mind that he will be able to fend for himself when his parents are no longer with him.

Again express my deepest thanks to you and Dr. Sanchez and tell you that I receive emails from people who consult for the experience of this surgery, of course my recommendations are in favor of this method and the prestigious experience of doctors Who carry it out.

Finally I regret that Pablo Ucha did not have the same fate as my son in terms of recovery, but this is the procedure, not everyone favors them in the same way.

We send our most sincere affections from Chile

Flora Alvarado, Chili

Dr. Mackliff’s letter to Flora explaining about the case of Pablo.

Dear friend

Ing. Flora Alvarrado

I would like to know how you are there in Calbulco.

I am particularly interested in knowing how Paulo is and what his general state of health is.

I only knew for Pablo Ucha that you had talked with his mother, and we are lamenting that this case is particularly under obsessive symptoms that were not eliminated with the operation.

I say goodbye, I wish the best for your family and I look forward to your kind answer.

Dr Jose Mackliff



Payments from Pharmaceutical Companies Influence Clinical Decision Making

Before trusting your child to a psychiatrist and their prescriptions for antipsychotic drugs, please read this chapter of my book A Life Worth Living – Schizophrenia Alternative Treatment. I’m going to lay out the facts for you in ten sections. I hope when you are done reading, you will understand that we are in a national crisis with mental healthcare for our children, and the choices we make are a matter of life or death for our children.

  • Payoffs from Pharmaceutical Companies to Psychiatrists
  • No Safe Dosage Levels Set for Antipsychotics by Pharmaceutical Companies or the FDA based on the safety and efficacy of antipsychotic drugs
  • International Consensus Study for Dosage of Antipsychotic Drugs conflicts with common dosages prescribed by US psychiatrists.
  • No Efficacy Studies for Antipsychotic Drugs for the Dosage Levels Commonly Prescribed by Psychiatrists. I found no studies done for dosages commonly prescribed or for durations over eighteen months nor for the dosage of Seroquel that my son was put on. All drug studies in medical schools and universities in the United States are funded by the pharmaceutical industry, and only studies on pharmaceuticals are funded.
  • World Health Organization’s Assessment of the Use of Antipsychotic Drugs in the United States.
  • No Legal Recourse for Mis-prescribing or Overprescribing Antipsychotic Drugs since no safe dosage levels are listed in the mandated medication information sheets nor are any required by the FDA (and the FDA is responsible for the safety and effectiveness of food and drugs).
  • Number of Adults, Adolescents, and Children in the United States on Antipsychotic Drugs as the First Line of Treatment for Schizophrenia, Bipolar Disorder, ADHD, and Aggression
  • Further Evidence of Pharmaceutical Paybacks Influencing Prescribing
  • National Alliance on Mental Illness (NAMI) Ties to Pharma

Is this an evil conspiracy between psychiatrists and drug companies? Are psychiatrists ill intended in their treatment of their schizophrenic patients? No. This is big business and how it operates without any controls and with an unsurpassable lobby group in Congress. Without safety guidelines (validated by long-term studies and accepting subjective data as real data) for commonly prescribed doses of antipsychotics, the psychiatrist makes his or her own decisions based entirely on his or her experience with his or her patients.

Unfortunately, the studies that have been done on antipsychotics demonstrate that the dosage and combination of drugs must be individualized for each patient.

Payoffs from Pharmaceutical Companies to Psychiatrists

In the United States, antipsychotics are prescribed to children and adolescents at a rate six times greater than the United Kingdom, which has socialized medicine and charges the same amount for any medicine. In June 2007, The New York Times reported that psychiatrists in Vermont and Minnesota topped the list of doctors receiving pharmaceutical company gifts and that this financial relationship corresponds to the “growing use of atypical (new antipsychotics) in children.” From 2000 to 2005, drug maker payments to psychiatrists in Minnesota rose more than six fold to $1.6 million. During these same years, prescriptions of antipsychotics for children under the state’s insurance program rose more than nine fold.

About Open Payments Database

Doctors and hospitals having financial relationships with health care manufacturing companies stimulated the creation of Open Payments, a federally run transparency program begun in 2014 that collects information about these financial relationships and makes it available to the public. These relationships can involve money for research activities, gifts, speaking fees, meals, or travel. One of the ways Open Payments provides this data to the public is through a search tool, which allows an individual to search for a doctor or teaching hospital that has received payments or a company that has made payments. Exploring this information and discussing the results found with your healthcare provider can help to make more informed healthcare decisions.
More information about the program can be found on the Open Payments website There you can get an overview of the data that’s been collected and displayed and learn more about the context around the data. For questions about the data, contact the Open Payments team at

One of my son’s psychiatrists is listed in the Open Payments Data; probably many psychiatrists are on this list, since receiving pharmaceutical paybacks is common practice in all specialties. Since this service has only been available since 2014 and two of the most prescribed antipsychotic drugs for schizophrenia Seroquel and risperidone became available in their generic form in 2014, the kickbacks listed were under $1,000 for my son’s doctor in 2014. This, however, doesn’t show how much they made while the drugs were still under the original patent name (which lasted for ten years) or when the patent name prescriptions are written for the government insurance plans to pay for.
The first prescription my son’s doctor wrote for us was for Seroquel. The price for a one-month prescription of Seroquel was $1,600 charged to Medicaid. Quetiapine, the generic form, was $400. The doctor changed the prescription to the generic name only when we requested it. Antipsychotic drugs represent the largest drug expenditure of the government insurance system in the United States. The doctor prescribed 1000mg day, 400mg over the highest tested amount by the manufacturer.

Like the Opioid epidemic in the U.S., we are in an epidemic of overprescribing psychotropic drugs with the motive of pure profit over-ruling a legitimate need for the drugs at the dosages prescribed.

Antipsychotic Drugs – How they Work & Why they don’t Work

“The precise mechanism by which the medicine works is unknown.” This is what is written in the drug information sheet for Seroquel, the second antipsychotic my son was put on. The drug manufacturer says, “This is a major area of research. One belief is that psychotic symptoms are related to over activity in the brain of the neurotransmitter dopamine. It is thought that antipsychotic medications reduce the activity of dopamine in the synaptic cleft. They do this by blocking the dopamine receptors—that is, preventing dopamine from attaching to the receptors. These medicines may also affect several other neurotransmitters in the brain, such as serotonin, norepinephrine, and glutamate. The overall purpose of anti-psychotic treatment is to restore the disturbed chemical balance of the brain.”

The hypothesis about the schizophrenic brain containing an excessive number of dopaminergic receptors explains some of the effects of the antipsychotics. It explains that when the dopaminergic receptors get blocked, the symptoms improve. It also explains how the antipsychotic drugs control behaviors but don’t cure schizophrenia. As soon as they are eliminated from the body, the receptors become free, and an excessive number of them start producing the schizophrenic pathology again (Mackliff, 2012).

Since 75 percent of young people diagnosed with schizophrenia stop taking the medicine during the first year and half of treatment because the side effects are so intolerable, the schizophrenic pathology begins again and again (New York State Mental Health, 2015).

The antipsychotic effect on schizophrenic patients hospitalized for a long time implies a permanent action on the cerebral synapses. The antipsychotic drug alters the capacity of the cell to respond to the synaptic impulse and furthermore alters its capacity to transmit information to other nervous cells. (Mackliff D. J., 2016)

Antipsychotics and BEAM

The benefits of BEAM surgery in Parkinson’s patients are immediate, in schizophrenic patients after two to three days. It is also important to understand that BEAM is a surgery that produces synaptic changes, signal transmission rate change, and genetic change. It helps to avoid antipsychotic increases in dopamine receptors in the limbic area because, after the operation, biochemical changes in the brains of schizophrenics occur immediately. The patient and his or her family need to work with the psychological effects of the patient’s recovery, and this takes time.

BEAM produces a change that antipsychotic drugs cannot perform, but antipsychotics in the indicated doses work perfectly on a schizophrenic patient who maintains a different synaptic plasticity, which he or she did not have before the BEAM operation.

Drug Industry plus Congress Fuels Opioid Addiction

Please watch this CBS 60 Minutes documentary on whistleblower, former DEA (Drug Enforcement Agency) Agent and Executive Chief of Office of Diversion Control, Joe Rannazzisi’s, findings about the PHARMA distributors behind the illicit traffic of narcotic pain killers in small mid-west and Eastern communities throughout the United States.


Whistleblower Joe Rannazzisi says drug distributors pumped opioids into U.S. communities — knowing that people were dying — and says industry lobbyists and Congress derailed the DEA’s efforts to stop it. Opioid addiction has become a national health crisis. How does President Trump respond to this crisis? He nominated Tom Marino, ex-DEA Lawyer, who wrote the bill derailing the enforcement division of DEA responsible for monitoring the Pharmaceutical industry’s drug distribution practices, as the Drug Czar for the federal government.

Update: President Trump announced Tuesday that his nominee for drug czar, Rep. Tom Marino, has withdrawn his name from consideration for the position.

In the midst of the worst drug epidemic in American history, the U.S. Drug Enforcement Administration’s ability to keep addictive opioids off U.S. streets was derailed — that according to Joe Rannazzisi, one of the most important whistleblowers ever interviewed by 60 Minutes. Rannazzisi ran the DEA’s Office of Diversion Control, the division that regulates and investigates the pharmaceutical industry. Now in a joint investigation by 60 Minutes and The Washington Post, Rannazzisi tells the inside story of how, he says, the opioid crisis was allowed to spread — aided by Congress, lobbyists, and a drug distribution industry that shipped, almost unchecked, hundreds of millions of pills to rogue pharmacies and pain clinics providing the rocket fuel for a crisis that, over the last two decades, has claimed 200,000 lives.

If you still have a deep-rooted belief in the pharmaceutical industry having your best interests in mind, please watch this ’60 Minutes’ documentary exposing the tremendous amount of influence the drug industry has in Congress which allows the drug industry to do what it wants, in the interest of profits alone. Antipsychotic drugs, the second most expensive drugs on the market, are a step away from the corruption exposed over illicit Opioid distribution by the drug industry. More to follow on this blog: The Pharmaceutical Industry’s illicit practices in promoting and controlling antipsychotic drugs as the only legal treatment for schizophrenia, the first line of treatment for bi-polar depression and other unapproved diagnoses.

BEAM Procedure – Why it Works

This procedure consists in blocking 100% of the production of Adrenaline from its source, and 20% of Noradrenaline from the adrenal marrow. Now the synthesis of Dopamine will have a new regulation; a new biochemical blueprint, and a new system of signals that causes for the shaking in Parkinson’s patients to disappear from the beginning, and the symptoms from schizophrenic patients to be eliminated.

This procedure was created by Ecuadorean Psychiatrist, Dr Jose Mackliff Hidalgo, after more than 30 years of research, and is now considered to be the most permanent solution to Parkinson and Schizophrenia available to date. The surgery consists of electrically burning the marrow in the narrow channel of the adrenal medullas which lie above the two kidneys in the body.

Adrenal Medulla glands-200

At the beginning of the decade of the 70’s, it was discovered that by increasing glucose, the aggressiveness in psychotic patients decreased. By 1974 Dr. Mackliff reviewed the results from a study by Hubell Von Vallet & Dell, in which the therapeutic effects of a drug called Clorpromazine on mental patients, were due precisely by inhibiting brain adrenaline.

By blocking the tissue in the suprarenal glands through the BEAM surgery, 100% of adrenaline, and 20% of noradrenaline, are also blocked in the blood stream and the symptoms in Parkinson and Schizophrenia disappear. Then in the brain, the glia and the hypothalamus detect the lack of these substances and their metabolisms are detected, and therefore, they take on the role of neuro-endocrine brain regulators, and start generating a new modal system, a new plasticity to the Tirosine chain; thus regulating the functions of Dopamine, Noradrenaline, and other neurotransmitters that communicate with these neurons. This way, Dopamine will be available in parts of the brain where it is only needed as in the “substantia nigra” in the case of Parkinson; and won’t be released in areas where it exists in excess, as in the “limbic zone” in the case of schizophrenia.

Why it Works

These were the results from the initial B.E.A.M surgeries done on dogs that had undergone drug-induced psychosis.

  • It may be possible that hyperglycemia prevents the release of glucoregulation hormones . Hyperglycemia prevents the release of adrenaline (epinephrine).
  • In this process, adrenaline is one of the most important hormones, because it is closely linked to the pathology of stress and monitoring of emotion. This is the only solution for the glucoregulation disorder and a new role system of H.P.A axis
  • It is easy to deduce that if the final element of the biochemical chain of tyrosine (epinephrine) is blocked, then the whole chain changes the synthesis and delivery of Dopa, dopamine, and noradrenaline. The brain takes on the role of providing the noradrenaline needed for the production of dopa and dopamine.
  • This means that if the role of epinephrine stops for eight hours of hyperglycemia with hypertonic solution, then this changes the blood homeostatic balance in the blood and brain and has an impact on the hypothalamic-pituitary-thyroid axis.
  •  On a biological level of analysis, much of the research has focused on the neuroendocrine system, particularly in the limbic-hypothalamic-pituitary-adrenal axis (LHPA).

Most Ecuadorian and foreign patients seeking operations are chronic, with more than ten years of schizophrenia or Parkinson and a long history of internment in the first. These patients with the help of antipsychotics and B.E.A.M have obtained a formidable elimination of positive and negative symptoms, as well as a better quality of life that is not possible with antipsychotics alone.

In Dr. Mackliff’s experience, patients with one to three years of schizophrenia (between 14 and 18) have a spectacular improvement in about 3-6 months after the operation. These cases correspond to 10% of the cases submitted to B.E.A.M, since most come to be operated when they are fully impaired, however they too obtain the elimination of symptoms.

Every case that has undergone B.E.A.M is unique and the patients live in homes with features and different environments which can impact positively or negatively on the operated patient.


It is interesting to note that the pharmaceutical industry spends billions $ on research on anti-depressant and antipsychotic drugs, and has virtually nothing to show for it. It has all been spent on useless studies designed to minimize the adverse effects of the drugs and the cerebral changes that result from their long term use.

Dr Mackliff has self-funded his entire research for 30 years and has now had over 110 successful surgeries on people with chronic schizophrenia since 2006. He presented his work and a case study of Sergio to the World – Neuro Talks in 2015 in Hangzhou, China with positive responses and results which may lead to formalizing the research into BEAM in the future. He is scheduled to present BEAM again at the 2018 World Congress Neurotalk conference with more case studies.